TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17038057

Group type: EXPERIMENTAL
Intervention: Siwak
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of Siwak and orthodontic toothbrush
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Siwak (used solely)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Siwak (in combination with orthodontic toothbrush)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 40

Group type: COMPARATOR
Intervention: Orthodontic toothbrush
Number of subjects: 40
Study: 12675949

Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Lecture-Based Learning (LBL)
Number of subjects: 112
Study: 12198777

Group type: EXPERIMENTAL
Intervention: Stimulus duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus contrast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duration of a blank gap between successive presentations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence or absence of a noise mask
Number of subjects: 0
Study: 7782903

Group type: EXPERIMENTAL
Intervention: Diet low in folate and exogenous methyl groups, soy-product-amino acid defined diet for 45 d, 25 micrograms/d of folate for 30 d, 99 micrograms/d for 15 d, supplemented with methionine for half the subjects.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low methionine and choline diet supplemented with methionine for half the subjects.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dietary restriction of methyl groups (low methionine and choline).
Number of subjects: 10
Study: 1776352

Group type: EXPERIMENTAL
Intervention: Retrograde Venous Perfusion (RVP) treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG) treated with systemic i.v. infusions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RVP treatment in patients with secondary osteomyelitis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG) with secondary osteomyelitis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RVP treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study: 6894606

Group type: EXPERIMENTAL
Intervention: Subcutaneous killed poliovirus vaccine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Subcutaneous poliovirus vaccination
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Peroral liver poliovirus vaccine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Peroral liver poliovirus vaccine with subcutaneous killed Vibrio cholerae vaccine
Number of subjects: 2
Study: 6199764

Group type: EXPERIMENTAL
Intervention: VDD pacing (Medtronic #2409, ASVIP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: VDD pacing
Number of subjects: 8
Study: 26856360

Group type: EXPERIMENTAL
Intervention: Knew the victim or perpetrator (SA scenario)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Knew the victim or perpetrator (IPV scenario)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Knew neither the victim nor the perpetrator (both scenarios)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Men (SA scenario)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Women (IPV scenario)
Number of subjects: 721
Study: 26253887

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 g intraoperatively and 15 mg/kg for an additional 3 days)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no methylprednisolone)
Number of subjects: 118
Study: 24535350

Group type: EXPERIMENTAL
Intervention: Fiber post and core with normal alveolar bone height (Group A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ni-Cr cast post and core with normal alveolar bone height (Group B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fiber post and core with 2 mm alveolar bone height reduction (Group C)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ni-Cr cast post and core with 2 mm alveolar bone height reduction (Group D)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fiber post and core with 4 mm alveolar bone height reduction (Group E)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ni-Cr cast post and core with 4 mm alveolar bone height reduction (Group F)
Number of subjects: 48
Study: 22684738

Group type: EXPERIMENTAL
Intervention: Remifentanil Ce = 2 ng ml(‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Remifentanil Ce = 4 ng ml(‐1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CARDEAN > 60 during surgery
Number of subjects: 18
Study: 19816214

Group type: EXPERIMENTAL
Intervention: Static stretching for 10 minutes with a 30-second hold
Number of subjects: 10

Group type: COMPARATOR
Intervention: No static stretching (control)
Number of subjects: 10
Study: 17084395

Group type: EXPERIMENTAL
Intervention: hCG administration during IVF cycles
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: Declining E(2) levels after hCG administration
Number of subjects: 844
Study: 15692762

Group type: EXPERIMENTAL
Intervention: Doxorubicin 75 mg/M2 q2 wks x 3 and docetaxel 40 mg/M2 weekly x 6
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Doxorubicin and docetaxel
Number of subjects: 70
Study: 12427893

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (IFNbeta‐1a)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Lesion volumes measured during the original trial
Number of subjects: 172
Study: 10599371

Group type: EXPERIMENTAL
Intervention: Tauredon (50 mg/week intramuscularly)
Number of subjects: 40
Study: 7556989

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 1.25 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5.0 mg
Number of subjects: 13
Study: 2031637

Group type: EXPERIMENTAL
Intervention: Thumb and index finger grip
Number of subjects: 16

Group type: COMPARATOR
Intervention: Whole hand technique
Number of subjects: 16
Study: 6110384

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg or 30 mg orally 1 hour before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo of identical appearance
Number of subjects: 60
Study: 31577875

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy for 28 weeks (immediate group)
Number of subjects: 956

Group type: COMPARATOR
Intervention: Isoniazid preventive therapy for 28 weeks (deferred group)
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (immediate group)
Number of subjects: 956

Group type: COMPARATOR
Intervention: Isoniazid preventive therapy (deferred group)
Number of subjects: 956
Study: 29632870

Group type: EXPERIMENTAL
Intervention: Dopamine D2/D3 receptor antagonist sulpiride
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 26657824

Group type: EXPERIMENTAL
Intervention: Loulla (liquid formulation of 6-mercaptopurine)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Registered tablets (control)
Number of subjects: 15
Study: 25320240

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5924

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 5924
Study: 22288567

Group type: EXPERIMENTAL
Intervention: GSK2248761
Number of subjects: 0
Study: 19594606

Group type: EXPERIMENTAL
Intervention: Late leakage (LL) group
Number of subjects: 234

Group type: COMPARATOR
Intervention: No leakage (NL) group
Number of subjects: 234
Study: 17656827

Group type: EXPERIMENTAL
Intervention: Memantine 20mg/day
Number of subjects: 470

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 470
Study: 15659587

Group type: EXPERIMENTAL
Intervention: Heart and Soul Physical Activity Program (HSPAP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison groups
Number of subjects: 42
Study: 12378877

Group type: EXPERIMENTAL
Intervention: Psychopharmacotherapy combined with cognitive behavioural therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Psychopharmacotherapy only
Number of subjects: 40
Study: 10594487

Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200 mg disulfiram
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 mg itraconazole
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 250 ml grapefruit juice twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 250 mg erythromycin 4 times daily
Number of subjects: 30
Study: 7565149

Group type: EXPERIMENTAL
Intervention: Experimental condition with varying ability to understand sexual relationship concepts
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 4
Study: 1950721

Group type: EXPERIMENTAL
Intervention: TCu200 IUD with marker strings
Number of subjects: 1265

Group type: COMPARATOR
Intervention: TCu200 IUD without marker strings
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1265
Study: 6753912

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 221
Study: 29267900

Group type: EXPERIMENTAL
Intervention: Prognostic nomograms for one-year overall survival
Number of subjects: 22674

Group type: EXPERIMENTAL
Intervention: Prognostic nomograms for six-month progression-free survival
Number of subjects: 22674
Study: 26874645

Group type: EXPERIMENTAL
Intervention: Tolvaptan (15 mg/d, titrated to 30 or 60 mg/d)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 25278086

Group type: EXPERIMENTAL
Intervention: PHiD-CV Commercial lot
Number of subjects: 466

Group type: COMPARATOR
Intervention: PHiD-CV Clinical lot
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 466
Study: 22740283

Group type: EXPERIMENTAL
Intervention: BICON-PLUS NT acetabular cup
Number of subjects: 0

Group type: COMPARATOR
Intervention: BICON-PLUS acetabular cup
Number of subjects: 0
Study: 19554028

Group type: EXPERIMENTAL
Intervention: Lower intensity training (33% of HR reserve)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher intensity training (66% of HR reserve)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (sedentary period)
Number of subjects: 0
Study: 17506866

Group type: EXPERIMENTAL
Intervention: Cardio-selective beta(1)-adrenergic blockade (0.15 mg kg(‐1) metoprolol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Moderate (105 +/- 11 W) and heavy (162 +/- 8 W) intensity cycling
Number of subjects: 8
Study: 16298888

Group type: EXPERIMENTAL
Intervention: Short study time with original context reinstated
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Long study time with original context reinstated
Number of subjects: 456

Group type: COMPARATOR
Intervention: Short study time without original context reinstated
Number of subjects: 456

Group type: COMPARATOR
Intervention: Long study time without original context reinstated
Number of subjects: 456

Group type: COMPARATOR
Intervention: No contextual or inter-item associative cues
Number of subjects: 456
Study: 11927516

Group type: EXPERIMENTAL
Intervention: Inhalation of concentrated ambient fine particles (CAP) plus ozone (120 ppb) for 2 hours
Number of subjects: 25

Group type: COMPARATOR
Intervention: Filtered air inhalation
Number of subjects: 25
Study: 9583759

Group type: EXPERIMENTAL
Intervention: Nurse clinician‐mediated intervention including pain assessment, education about pain control, patient empowerment, and communication with healthcare providers.
Number of subjects: 4804

Group type: EXPERIMENTAL
Intervention: Nurse clinician‐mediated intervention
Number of subjects: 4804

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 4804
Study: 8137988

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment to induce immunosuppression
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 2683546

Group type: EXPERIMENTAL
Intervention: General anaesthesia (Group I, n = 29)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (Group II, n = 29)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia with lower isoflurane concentration (Group III, n = 22)
Number of subjects: 80
Study: 30456542

Group type: EXPERIMENTAL
Intervention: Robotic TKA
Number of subjects: 351

Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 351
Study: 26525835

Group type: EXPERIMENTAL
Intervention: Cardiovascular training (CT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both training programs (CT and RT)
Number of subjects: 63
Study: 24671637

Group type: EXPERIMENTAL
Intervention: Preoperative exercise
Number of subjects: 72

Group type: COMPARATOR
Intervention: Surgery-alone
Number of subjects: 72
Study: 22032343

Group type: EXPERIMENTAL
Intervention: Catechin-rich green tea plus inulin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (650 ml tea)
Number of subjects: 30
Study: 20176314

Group type: EXPERIMENTAL
Intervention: Very brief (30-second) smoking intervention
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control no-intervention condition
Number of subjects: 295
Study: 18951004

Group type: EXPERIMENTAL
Intervention: High-DHA milk (1% total fat as DHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-DHA milk (0.2-0.3% DHA)
Number of subjects: 0
Study: 16911649

Group type: EXPERIMENTAL
Intervention: Topical racemic adrenaline (RA) 1:500
Number of subjects: 93

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (physiological saline)
Number of subjects: 93
Study: 14719288

Group type: EXPERIMENTAL
Intervention: Da Ding Feng Zhu Decoction
Number of subjects: 56

Group type: COMPARATOR
Intervention: Colchicine
Number of subjects: 56
Study: 11110056

Group type: EXPERIMENTAL
Intervention: 40 mg toremifene
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 20 mg tamoxifen
Number of subjects: 141

Group type: COMPARATOR
Intervention: No adjuvant systemic therapy
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 141
Study: 8986909

Group type: EXPERIMENTAL
Intervention: Losartan (50-100 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7708425

Group type: EXPERIMENTAL
Intervention: Trained paraplegics (TP) in hot climate (37 degrees C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Able-bodied subjects (AB) in hot climate (37 degrees C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Trained paraplegics (TP) in cool climate (15 degrees C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Able-bodied subjects (AB) in cool climate (15 degrees C)
Number of subjects: 10
Study: 3068399

Group type: EXPERIMENTAL
Intervention: Urokinase (1,000,000 IU)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 129
Study: 31012566

Group type: EXPERIMENTAL
Intervention: Epicutaneous heat patch applied for 2 hours per day for 12 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Epicutaneous heat patch
Number of subjects: 15

Group type: COMPARATOR
Intervention: Untreated wart observation
Number of subjects: 15
Study: 28943323

Group type: EXPERIMENTAL
Intervention: Primary Anastomosis (PA)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Hartmann's Procedure (HP)
Number of subjects: 102
Study: 26927664

Group type: EXPERIMENTAL
Intervention: Haploidentical donor HSCT (n = 103)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Matched-sibling donor HSCT (n = 83)
Number of subjects: 210
Study: 23299843

Group type: EXPERIMENTAL
Intervention: Community education campaigns, enforcement of environmental regulations, and a wood heater replacement programme to reduce ambient pollution from residential wood stoves started in the winter of 2001.
Number of subjects: 215000

Group type: COMPARATOR
Intervention: Control group (central Hobart, no specific air quality interventions).
Number of subjects: 215000
Study: 21916638

Group type: EXPERIMENTAL
Intervention: Malaria vaccine FMP2.1/AS02(A)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (rabies vaccine)
Number of subjects: 400
Study: 19806414

Group type: EXPERIMENTAL
Intervention: Walking Program (WP)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Walking Program plus Pedometer (WPP)
Number of subjects: 314

Group type: COMPARATOR
Intervention: No Treatment Control (C)
Number of subjects: 314
Study: 16625235

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (20 min at 75% heart rate reserve)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control day (no exercise)
Number of subjects: 16
Study: 15267121

Group type: EXPERIMENTAL
Intervention: Submucosal haemorrhoidectomy with radiofrequency bistoury (Group A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Diathermic haemorrhoidectomy (Group B)
Number of subjects: 31
Study: 11411059

Group type: EXPERIMENTAL
Intervention: Metformin (2 x 850 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8677878

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at dosages of 10 to 320 ng/kg/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at dosages of 40 ng/kg/min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diltiazem pretreatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at dosages > 80 ng/kg/min
Number of subjects: 0
Study: 1659913

Group type: EXPERIMENTAL
Intervention: Colposcopic examination
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Colposcopic directed biopsies
Number of subjects: 100
Study: 6539789

Group type: EXPERIMENTAL
Intervention: 50 msec laser pulses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 msec laser pulses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous application of the argon laser
Number of subjects: 0
Study: 31036542

Group type: EXPERIMENTAL
Intervention: NP-S + GM-CSF (1,000 μg NP-S + 250 μg GM-CSF monthly for 6 months, then every 6 months through 36 months)
Number of subjects: 758

Group type: COMPARATOR
Intervention: Placebo + GM-CSF (monthly for 6 months, then every 6 months through 36 months)
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: NP-S + GM-CSF
Number of subjects: 758

Group type: COMPARATOR
Intervention: Placebo + GM-CSF
Number of subjects: 758
Study: 27768613

Group type: EXPERIMENTAL
Intervention: Palliative care in high‐risk patients targeted by an Early Warning System
Number of subjects: 206
Study: 26118831

Group type: EXPERIMENTAL
Intervention: Pharmacy-randomized intervention with in-depth harm reduction training and additional services (HIV prevention/medical/social service referrals, syringe disposal containers, harm reduction print materials)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Primary control pharmacies (recruited syringe customers but did not offer additional services)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Secondary control pharmacies (did not recruit syringe customers)
Number of subjects: 482
Study: 23682696

Group type: EXPERIMENTAL
Intervention: CARE intervention (nurse-led home visits)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (nurse attention during data collection)
Number of subjects: 134
Study: 21480266

Group type: EXPERIMENTAL
Intervention: Brown Rice (BR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: White Rice (WR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Polished Brown Rice (PR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Glucose Reference (GLU)
Number of subjects: 9
Study: 19678966

Group type: EXPERIMENTAL
Intervention: CBT with low-carbohydrate diet (CBT-LC)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CBT with low-fat diet (CBT-LF)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control with low-carbohydrate diet (C-LC)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control with low-fat diet (C-LF)
Number of subjects: 105
Study: 18075937

Group type: EXPERIMENTAL
Intervention: Consumer-operated services (COSPs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study: 15250751

Group type: EXPERIMENTAL
Intervention: Tiotropium plus usual care
Number of subjects: 921

Group type: COMPARATOR
Intervention: Usual care alone (placebo)
Number of subjects: 921
Study: 11487161

Group type: EXPERIMENTAL
Intervention: AH-Plus
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Apexit
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ketac-Endo
Number of subjects: 75

Group type: COMPARATOR
Intervention: Positive Control
Number of subjects: 75

Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 75
Study: 9772873

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8631101

Group type: EXPERIMENTAL
Intervention: Subcuticular suture skill
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine suture skill
Number of subjects: 200
Study: 2510657

Group type: EXPERIMENTAL
Intervention: Cadralazine 10 mg o.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1159434

Group type: EXPERIMENTAL
Intervention: Anticoagulants for an average period of 18 months
Number of subjects: 49

Group type: COMPARATOR
Intervention: Supportive treatment
Number of subjects: 49
Study: 30580224

Group type: EXPERIMENTAL
Intervention: TL-eSET (time-lapse monitoring)
Number of subjects: 161

Group type: COMPARATOR
Intervention: control-eSET (standard evaluation)
Number of subjects: 161
Study: 28835271

Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D3 daily
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 25877802

Group type: EXPERIMENTAL
Intervention: Zinc Glycinate (60 mg Zn/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Zinc Gluconate (60 mg Zn/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24157649

Group type: EXPERIMENTAL
Intervention: EHR-based medication management tools alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EHR tools plus nurse-led medication therapy management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 21748203

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 μg intravaginally every 4 hours (maximum 6 doses)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 113
Study: 20201401

Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 522

Group type: COMPARATOR
Intervention: Symptomatic therapy
Number of subjects: 522

Group type: COMPARATOR
Intervention: Not treated with Cycloferon
Number of subjects: 522